The discovery of free fetal DNA (ffDNA) 11 in maternal circulation (1 ) marked the beginning of the noninvasive prenatal testing (NIPT) era, and allowed the development of the first noninvasive prenatal tests. ffDNA has been successfully used for the determination of fetal sex and fetal rhesus D status in maternal plasma (2, 3 ) . These methods have become routine in a number of clinical laboratories worldwide. However, direct analysis of the limited amount of ffDNA in the presence of an excess of maternal DNA presents a great challenge for NIPT.
The percentage of ffDNA in maternal circulation was originally estimated to be 3%-6% of the total cell free DNA (4 ) . However, recent studies suggest that fetal fraction can be as high as 10%-20% (5 ) . The presence of such high amounts of maternal DNA in maternal circulation in relation to the limited amount of fetal DNA poses a major challenge for the quantification of fetal DNA and the detection of fetal aneuploidies.
Over the last decade a large number of different methods have been applied to allow the discrimination or enrichment of ffDNA from circulating maternal DNA (6 ) . The DNA-based approaches include sequencing and epigenetics based assays, which focus on the investigation of the methylation status of fetal DNA either using sodium bisulfite DNA treatment (7 ), methylationsensitive restriction enzymes, or antibodies specific to the 5-methylcytosine residues of CpG dinucleotides across the genome (8 -10 ) . Alternative approaches have targeted fetal-specific mRNA (11 ) or have focused on the investigation of fetal-specific proteins (12 ) .
The use of next generation sequencing (NGS) technologies in NIPT has revolutionized the field. In 2008, 2 independent groups demonstrated that NIPT of trisomy 21 (T21) could be achieved using massively parallel shotgun sequencing (13, 14 ) , ushering in a new era of NIPT and opening new possibilities for the use of these technologies in clinical practice. On the basis of these findings, biotechnology companies and independent groups initiated clinical studies and developed new NIPT tests (15) (16) (17) (18) (19) (20) (21) .
More recently, targeted NGS approaches, in which only specific sequences of interest are used, have been developed. A single nucleotide polymorphism-based NGS approach involving multiplex targeted amplification and analysis of single nucleotide polymorphisms and a quantitative NGS approach that uses ligated probes that are then amplified and sequenced have been described (20, 21 ) . Targeted approaches have the potential to increase throughput and reduce cost because they require substantially less sequencing than whole genome sequencing approaches.
Nevertheless, the development of even more accurate, cost-effective NIPT methods is greatly needed. In particular, approaches that can target specific sequences of interest, thereby reducing the amount of sequencing needed compared to whole genome-based approaches, can be extremely advantageous. Here we present a highly accurate and cost-effective method for the detection of fetal trisomies 21, 18, and 13, which overcomes many of the limitations of the current NIPT technologies.
Materials and Methods

SAMPLE COLLECTION
Plasma samples were obtained anonymously from pregnant women of at least 18 years of age from the 10th week of gestation. Only singleton pregnancies were analyzed. Protocols used for sample collection were approved by the National Bioethics Committees and informed consent was obtained from all participants. Referring centers were provided with all relevant information about eligibility criteria, benefits, and limitations of participating in this study (22 ) . The aneuploid cases enrolled in this study consisted of T21, trisomy 18 (T18), and trisomy 13 (T13) pregnancies, which were confirmed via invasive testing.
SAMPLE COLLECTION AND PREPARATION
A mean of 8 mL of peripheral blood was collected from each subject into EDTA-containing tubes. A mean of 4 mL of plasma was isolated via a double centrifugation protocol of 1600 ϫ g for 10 min, followed by 16 000 ϫ g for 10 min. Plasma samples were given a unique identifier and were stored at Ϫ80°C until subsequent analysis. ffDNA was extracted from 4 mL plasma using the Qiasymphony DSP Virus/Pathogen Midi Kit (Qiagen).
SEQUENCING LIBRARY PREPARATION
Extracted DNA was processed using standard library preparation methods with minor modifications (23 ) . Negative-control libraries were also prepared. In summary, 5Ј and 3Ј overhangs were filled-in using T 4 polymerase (NEB) and 5Ј phosphates were attached using T 4 polynucleotide kinase (NEB). Reaction products were purified using the MinElute kit (Qiagen). Subsequently, sequencing adaptors were ligated to both ends of the DNA using T 4 DNA ligase (NEB), followed by purification using the MinElute kit (Qiagen). Nicks were removed in a fill-in reaction using Bst polymerase (NEB) with subsequent incubation at 65°C for 25 min and then 12°C for 20 min. Library amplification was performed using Fusion polymerase (Agilent Technologies) and all samples were assigned a unique barcode. Sequencing library products were purified using the MinElute purification kit (Qiagen).
DESIGN AND PREPARATION OF TARGET CAPTURE
SEQUENCES
Custom target capture sequences (TACS) of approximately 250 bp were designed to capture selected loci on chromosomes 21, 18, 13, and Y (see Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/ vol62/issue6). The genomic target-loci were selected on the basis of GC content, distance from repetitive elements, and absence of surrounding complex genomic architecture. The TACS were prepared by polymerase chain reaction using MyTaq polymerase (Bioline) and primers designed to amplify the target-loci in normal DNA. Amplicons were verified by agarose gel electrophoresis and were purified using standard PCR clean up kits such as the Qiaquick PCR purification kit (Qiagen) or the NucleoSpin 96 PCR clean-up kit (Macherey Nagel). TACS concentration was measured using the Nanodrop spectrophotometer (Thermo Scientific). TACS were pooled equimolarly, and were blunt ended using the Quick Blunting kit (NEB). Following purification using the MinElute kit (Qiagen), they were biotinylated using the Quick Ligation Kit (NEB) and were purified using the MinElute kit (Qiagen). The TACS (1500 ng) were then immobilized on streptavidincoated magnetic beads (Invitrogen) as previously described (24 ) .
HYBRIDIZATION
Amplified libraries were mixed with hybridization buffer (Agilent), blocking agent (Agilent), blocking oligonucleotides (25 ), Cot-1 DNA (Invitrogen), and salmon sperm DNA (Invitrogen). Sequencing library hybridization mixtures were then denatured at 95°C for 3 min and were incubated at 37°C for 20 min before being added to the biotinylated TACS. The samples were then incubated for 12-48 h at 66°C and were washed as previously described (24 ) . Captured sequences were eluted by heating. Eluted sequences were amplified using outerbound adaptor primers. Enriched amplified products were pooled equimolarly and were sequenced on a MiSeq, NextSeq 500, or Hiseq 2500 sequencing platform (Illumina).
DATA ANALYSIS
Alignment to the human reference genome. Paired-end read fragments of each sample were processed using the Cutadapt software (26 ) to remove adaptor sequences and poor-quality reads. The remaining sequences were aligned to the human reference genome build hg19 (UCSC Genome Bioinformatics) using the BurrowsWheeler alignment algorithm (27 ) . The Picard tools software suite [Broad Institute (2015) Picard] was used to remove duplicate read entries and convert aligned reads to a binary (BAM) file containing uniquely aligned read entries. Per base read-depth information was retrieved from this final BAM file using the SAMtools software suite. Single nucleotide polymorphism information across the targeted sequences was obtained using the bcftools suite of functions and the vcfutils.pl script, which accompany the SAMtools software suite (27 ) .
Classification of fetal aneuploidy. The sequencing procedure introduces read-depth discrepancies across many regions of interest. This bias is in part dependent on the GC-content of each sequenced region (28 ) . GC-bias alleviation was achieved by estimating each region's GC content and subsequently grouping the read-depth of similar GC-content regions together to create matching groups. Matching groups from the test chromosome were compared to the corresponding matching groups on the reference chromosomes using 3 statistical tests: a paired t-test, a bivariate nonparametric bootstrap, and a stratified permutation test. The score obtained from each method was used to calculate a weighted sum. To account for run-to-run bias (29 ) , each weighted sum was normalized by subtracting the run-specific median and then dividing by a multiple of the empirical standard deviation of euploid samples. The run-specific median was calculated from the weighted sums of all samples in a sequencing run. The theoretical variance of the random variable denoted by the weighted sum of the 3 methods was estimated from a training set of 100 euploid samples. This normalized score was used to estimate the trisomy risk (tririsk) of each sample. Scores above a specific threshold were classified as high-risk for trisomy.
Estimation of fetal fraction.
A finite (binomial) mixture model based on Bayesian inference (30 ) was developed and used to compute the posterior distribution of fetal DNA fraction using allelic counts at heterozygous loci in maternal plasma. Three possible informative combinations of maternal/fetal genotypes were used within the model to identify fetal DNA fraction values that were strongly supported by the observed data. The posterior distribution of fetal fraction was calculated using a Metropolis-Hastings algorithm (31 ) . The lower bound of the 95% credible interval of this posterior probability distribution was subsequently inferred.
Results
A total of 631 plasma samples were analyzed in this blind study, including 52 T21, 16 T18, and 5 T13 pregnancies from women who had undergone invasive procedures (Fig. 1) . One sample did not pass the sequencing library quality control criteria and was excluded from the analysis. Another 19 samples (14 normal, 3 T18, 2 T13) exhibited an insufficient ffDNA fraction of Ͻ4% and were excluded from the analysis. Fig. 2 summarizes the demographic characteristics of all 631 samples. The median maternal age was 36 years, the median maternal weight was 63 kg, and the median gestational age was 16 weeks.
Tririsk scores for T21, T18, and T13 were assigned to the 611 samples that passed all quality control criteria (Fig. 3) . Samples with a tririsk score exceeding a threshold of 1 were classified by the classification analysis algorithm as trisomic. A posteriori analysis of the validation data set suggested that this threshold could be as low as 0.91 (see online Supplemental Fig. 1 ). T21 was detected in 52/52 cases (95% CI, 93.2% to 100%) (Fig. 3A) . T18 was detected in 16/16 cases (95% CI, 79.4% to 100%) (Fig. 3B) and T13 was detected in 5/5 cases (95% CI, 47.8% to 100%) (Fig. 3C) . These results are summarized in Table 1 .
The fetal fraction distribution of all cases can be seen in online Supplemental Fig. 2 . The mean fetal fraction of all samples was 10.9% with an SD of 4.1%. As shown in Fig. 4 , there was no association between fetal fraction and tririsk scores in normal samples (Pearson correlation test p-values Ͼ0.4 for all 3 aneuploidy tests), although there was a clear association between these variables in trisomic samples. Specifically, a Pearson correlation test evaluating the association between tririsk scores and fetal fraction in T21, T18, and T13 samples resulted in p-values of 0.0014, 0.0002, and 0.0164 respectively.
Discussion
This study used a targeted assay that employed target capture sequences and a novel analytical algorithm to detect fetal trisomies 21, 18, and 13. In a blind validation study, which included 631 pregnant women of at least 10 weeks of gestation, the assay results exhibited 100% diagnostic sensitivity and specificity and correctly classified 52/52 cases of T21, 16/16 cases of T18, and 5/5 cases of T13, in all samples that passed quality control criteria (n ϭ 611). The test also correctly identified fetal sex in all cases.
In this study we focused our analysis on chromosomes 21, 18, and 13, and determined that an optimized set of approximately 1500 loci was sufficient to enable highly accurate fetal aneuploidy detection. We also tested alternative sets consisting of fewer TACS and/or TACS of variable GC content. These experiments allowed us to determine that the most important technical factor affecting the performance of the assay was the number of TACS on different chromosomes that exhibited similar GC-content characteristics, thus allowing for more robust GC-bias correction. We observed that this was more pronounced on chromosome 18, where 1 T18 sample was classified as normal when sets of TACS that were not optimally matched for GC-content were used. These results indicated that the assay was sensitive to TACS GCcontent differences, and enabled us to construct an optimal set of TACS on chromosomes 21, 18, and 13 that resulted in the correct classification of all normal and trisomic cases (Fig. 3) .
Our assay employs a robust analysis algorithm that minimizes random and systemic variation between sequencing runs and is sensitive enough to distinguish between euploid and aneuploid samples. There is a clear separation between the risk scores of trisomic and disomic samples (Fig. 3) , allowing a binary classification scheme.
The targeted test described here constitutes an integrated assay that incorporates simultaneous determination of fetal fraction and accurate detection of fetal aneuploidies. The algorithm uses a Bayesian approach to estimate fetal DNA fraction. As such, additional information can be easily incorporated into the model. In addition, instead of inferring a point estimate of fetal DNA fraction, the algorithm calculates the posterior distribution of the fetal DNA fraction in each sample. It subsequently uses the lower bound of the corresponding 95% credible interval to determine whether a sample has adequate fetal fraction. This conservative approach of estimating fetal fraction ensures that the lowest possible fetal fraction of each sample is considered for classification purposes, thus minimizing the possibility of incorrect calls that could potentially arise from low proportions of fetal DNA. This novel fetal fraction estimation algorithm was also independently and thoroughly validated using Y-chromosome loci in male samples. The fetal fraction estimation algorithm was also tested using nonpregnant samples. The algorithm correctly identified the absence of fetal DNA in these samples.
This study identified 3 T18 and 2 T13 samples that had low fetal fraction. This further illustrates the need for accurate fetal fraction estimation in NIPT to avoid false negative (FN) results (32 ) . The targeted assay described here is inherently characterized by high depth of sequencing, which allows highly accurate fetal fraction quantification and aneuploidy detection. In the clinical setting it is of paramount importance that low fetal fraction Nineteen samples were excluded from the analysis because of low fetal fraction, and 1 sample was excluded because of technical reasons. The remaining cohort of 611 samples consisted of 538 normal samples, 52 T21 samples, 16 T18 samples, and 5 T13 samples.
Targeted NIPT for Fetal Aneuploidies samples are identified so that a redraw sample is requested for reanalysis.
The current study evaluated samples from multiple centers in the form of a simple streamlined assay that can be easily implemented in a clinical setting. Future work will focus mainly on first trimester samples and low-risk pregnancies, because NIPT tends to gradually migrate from second to first trimester screening, and from high to intermediate and low-risk pregnancies. Our data suggests that this assay will exhibit the same exceptional accuracy in both low and high risk pregnancies.
The targeted noninvasive prenatal assay described here has several advantages compared to whole genome sequencing methods. Whole genome sequencing requires a very large number of reads and only allows the simultaneous analysis of very few samples. The inherently limited throughput of whole genome methods imposes a significant financial and logistical burden. In contrast, the targeted method described here uses only specific genomic regions and significantly reduces the number of required reads. This results in a dramatic increase in efficiency and a significant reduction in overall costs. At the same time, the enrichment of only specific genomic regions allows for optimal GC-bias correction and enables high enrichment levels, which result in very accurate aneuploidy detection. The targeted nature of the assay also ensures extremely high accuracy by enabling robust fetal fraction estimation and by avoiding copy number variants or other complex genomic architectural elements which can cause false positive (FP) or FN results (33, 34 ) .
Although NIPT has major advantages compared to conventional screening approaches, a number of challenges remain. It has been noted that feto-placental mosaicism can result in discordant findings between NIPT and fetal karyotyping (35 ) . Chromosomal mosaicism in chorionic villus samples is detected in 1%-2% of cases, and can involve different numerical and structural chromosomal abnormalities and feto-placental lineages (36 ) . True fetal mosaicism (TFM) is confirmed in only 13% of these cases, whereas in 87% the chromosomal abnormality is confined to the placenta [confined placental mosaicism (CPM)] (37 ). It is known that ffDNA circulating in maternal plasma originates from apoptosis of the cells of the outer layers of the placenta, i.e., the cytotrophoblast and syncytiotrophoblast cells (38 ) . Cases of mosaicism, in which the chromosomal constitution of the cytotrophoblast is different from that of the fetus, are potential sources of FP and FN results. CPM type I and III with an abnormal cytotrophoblast and normal amniocytes can cause FP results, whereas TFM type V with a normal cytotrophoblast and abnormal amniocytes can cause FN results (36 ) . The largest monocentric study examining chromosomal mosaicism in relation to NIPT results includes a retrospective audit of 52673 chorionic villus samples in which cytogenetic analysis of the cytotrophoblast (direct) and villus mesenchyme (culture) was performed, followed by confirmatory amniocentesis in chorionic villi mosaic cases (36 ) . According to this study the combined FP rate for T13, T18, and T21, would be 1 in 3006 cases, and the FN rate would be 1 in 107. Because both T13 and T18 pregnancies are highly likely to have abnormalities detectable by ultrasound investigation and will spontaneously abort between 12 weeks and term (39 ) , the main concern remains for FP and FN T21 results. Taking into consideration the incidence of T21 in the general population (40 ) and the incidence of TFM type V (36 ), the number of FN T21 cases is estimated to be approximately 1 in 100 000 NIPTs. Also, assuming that at least 70% CPM is needed to produce a FP T21 result (36 ) , the FP T21 rate would be approximately 1 in 13 000. Although these figures are very low, it is important to be aware of the genetic physiology of the placenta and the limitations it imposes on NIPT when contemplating its integration into safe clinical prenatal care.
A major objective in the field of prenatal testing is the reduction of the number of unnecessary invasive procedures. ffDNA testing can significantly reduce procedure-related losses while maintaining high detection rates. It provides clinicians and prospective parents with a powerful tool to help them make informed decisions regarding the need for an invasive procedure, without posing any risk to the pregnancy. The clinical impact of ffDNA testing has been significant as indicated by its quick adoption in prenatal care. The extent to which ffDNA testing can be applied as a universal screening tool for T21, 18, and 13 depends mainly on assay accuracy, low number of nonreportable tests, and cost. In this study we presented the development and validation of a novel, cost-effective and exceptionally accurate method for NIPT of aneuploidies of chromosomes 21, 18, and 13 and fetal sex.
